On a corporate action affecting ordinary shares of Poseida Therapeutics, Inc. (PSTX)

On November 26, 2024, Poseida Therapeutics, Inc. signed a merger agreement under which it will be acquired by Roche Holdings, Inc. Poseida Therapeutics, Inc. stockholders will receive $9.00 in cash and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 in cash for each share of Poseida Therapeutics, Inc. that they own. Transaction is expected to close in the first quarter of 2025. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.